Duracyte
Clinical-Stage Company | Advancing implantable drug factories with novel combination biologics
Cell therapy's core limitation is durability. Engineered cells exhaust and disappear, leaving patients vulnerable to relapse. Duracyte's HAMMR platform bypasses that problem entirely: implantable biohybrid pharmacy devices that enable continuous therapeutic protein production inside the body.
Lead indication is recurrent platinum resistant ovarian cancer. Manufacturing infrastructure is in place with GMP partners. A partnership with MD Anderson provides a direct clinical pathway.
Progress
ARPA-H committed $45 million
Multiple interactions with FDA including PreIND Meeting
IND enabling activities underway
Phase 1 trial advancing to the clinic
